Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program

The study evaluated the long-term efficacy of ritlecitinib 50 mg in patients with alopecia areata over a period of up to 3 years. Involving 191 patients, the study found that at months 36-38, 31.2% of observed patients and 22.5% of those using the last observation carried forward (LOCF) method achieved complete scalp hair regrowth (SALT score 0). Additionally, 65.1% of observed patients and 47.1% using LOCF achieved a SALT score ≤20, indicating significant hair regrowth. Among those who achieved a SALT score of 0 at any point, 84.2% maintained a SALT score ≤5 in subsequent visits. The study concluded that ritlecitinib 50 mg is effective in promoting hair regrowth in alopecia areata patients, with sustained results over time.